Biohaven's New Therapies Show Significant Antibody Reduction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: Newsfilter
- Efficacy of BHV-1300: In a 12-week study, patients with Graves' disease receiving 1000 mg of BHV-1300 weekly showed an average reduction of over 80% in pathogenic TSHR-IgG1 antibodies, indicating the drug's potential as a first effective disease-modifying therapy for Graves' disease.
- Rapid Normalization of Thyroid Hormones: Patients experienced normalization of T4 levels within a median of 3 weeks and T3 levels within 5 weeks after the first administration, demonstrating BHV-1300's ability to quickly restore thyroid function, addressing a critical unmet need for effective treatments.
- Rapid Action of BHV-1400: In patients with IgA nephropathy, BHV-1400 achieved over 60% mean reduction in Gd-IgA1 antibodies within 48 hours and 70% within one month, showcasing its rapid and profound impact on treating IgAN.
- Good Safety Profile: Both BHV-1300 and BHV-1400 showed no serious adverse events during clinical trials, with most adverse reactions being mild and self-resolving, indicating a competitive safety advantage that may encourage more patients to participate in upcoming Phase 3 trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 9.450
Low
11.00
Averages
18.00
High
30.00
Current: 9.450
Low
11.00
Averages
18.00
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biohaven Reports New Clinical Data on Innovative Therapies
- Clinical Data Release: Biohaven presented new patient data on its BHV-1300 MoDE degrader for Graves' disease and BHV-1400 TRAP degrader for IgA nephropathy at the Yale Innovation Summit, showcasing the potential of its therapies to transform treatment options for autoimmune diseases.
- R&D Day Event: The data was unveiled during Biohaven's 2026 R&D and Analyst Day at Yale School of Management, highlighting the company's innovative capabilities in the biopharmaceutical sector and its focus on autoimmune diseases, which may attract increased investor interest.
- Platform Technology Advantage: Biohaven's proprietary MoDE™ and TRAP™ degrader platforms demonstrate unique drug development capabilities that could provide a competitive edge in future clinical trials, enhancing its position in the biopharmaceutical market.
- Broad Market Prospects: With the rising number of autoimmune disease patients, Biohaven's new therapies are poised to address unmet medical needs, further driving the company's expansion and revenue growth in the global market.
See More
Biohaven's New Therapies Show Significant Antibody Reduction
- Efficacy of BHV-1300: In a 12-week study, patients with Graves' disease receiving 1000 mg of BHV-1300 weekly showed an average reduction of over 80% in pathogenic TSHR-IgG1 antibodies, indicating the drug's potential as a first effective disease-modifying therapy for Graves' disease.
- Rapid Normalization of Thyroid Hormones: Patients experienced normalization of T4 levels within a median of 3 weeks and T3 levels within 5 weeks after the first administration, demonstrating BHV-1300's ability to quickly restore thyroid function, addressing a critical unmet need for effective treatments.
- Rapid Action of BHV-1400: In patients with IgA nephropathy, BHV-1400 achieved over 60% mean reduction in Gd-IgA1 antibodies within 48 hours and 70% within one month, showcasing its rapid and profound impact on treating IgAN.
- Good Safety Profile: Both BHV-1300 and BHV-1400 showed no serious adverse events during clinical trials, with most adverse reactions being mild and self-resolving, indicating a competitive safety advantage that may encourage more patients to participate in upcoming Phase 3 trials.
See More
Biohaven Reports New Data on Opakalim for Epilepsy Treatment
- Clinical Trial Progress: Biohaven will present new data on Opakalim's Phase 2/3 studies for focal epilepsy at its upcoming R&D Day, indicating its potential to provide more effective treatment options for patients in seizure control.
- Safety Advantages: Opakalim demonstrated zero rates of somnolence, dizziness, and fatigue in a small proof-of-concept study, suggesting that its selective Kv7.2/7.3 activation mechanism may offer better tolerability, enhancing patients' quality of life.
- Patient Case Update: A 9-year-old patient with KCNQ2-DEE showed seizure control after transitioning to Opakalim, highlighting the drug's efficacy in treatment-resistant epilepsy patients and supporting its clinical application potential.
- Future Outlook: Biohaven is on track to announce top-line results from two pivotal Phase 2/3 randomized double-blind studies in the second half of 2026, aiming to support Opakalim's registration and advance its commercialization efforts.
See More
Biohaven Reports New Clinical Data on Opakalim for Epilepsy Treatment
- Breakthrough in Epilepsy Treatment: In a randomized controlled trial, the median time to the second generalized tonic-clonic seizure was 141 days for the Opakalim 75 mg once-daily group compared to 47 days for the placebo group, indicating a threefold prolongation and highlighting its potential in treating refractory epilepsy.
- Significant Efficacy: In an ongoing open-label extension study, 54% of patients with focal epilepsy achieved a ≥50% reduction in seizure frequency on Opakalim, demonstrating comparable efficacy to other Kv7 activators but with significantly lower side effects.
- Safety Advantage: Opakalim has shown excellent tolerability across studies, with over 1,000 subjects reporting adverse event rates below 5%, marking a significant improvement over other antiseizure medications in terms of central nervous system side effects.
- Future Outlook: Biohaven is on track to announce top-line results from two pivotal Phase 2/3 trials in the second half of 2026, which will support the registration of Opakalim and further solidify its market position in epilepsy treatment.
See More
Biohaven Q1 Earnings Miss Expectations
- Earnings Miss: Biohaven reported a Q1 GAAP EPS of -$0.88, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, Biohaven's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $351.8 million, providing some liquidity but necessitating scrutiny on future capital efficiency.
- Rating Downgrade Impact: The stock was downgraded to 'Hold' due to setbacks with Troriluzole and potential implications from obesity data expected in the second half of 2026, prompting a reassessment of the company's growth prospects.
- Market Reaction Outlook: Analysts' quant ratings reflect a cautious stance on Biohaven's future performance, urging investors to closely monitor subsequent financial and R&D developments to evaluate long-term investment value.
See More
Biohaven Stock Surges 10.14% Following Analyst Buy Rating
- Analyst Strong Buy: Sumant Kulkami from Canaccord Genuity initiated coverage on Biohaven with a bullish buy rating and a price target of $21 per share, indicating a potential upside of over 100% from current levels, reflecting strong confidence in the company's growth prospects.
- Clinical Trial Progress: Biohaven's drug Opakalim is currently in phase 3 clinical testing for epilepsy, and Kulkami expressed satisfaction with its performance, suggesting significant potential for commercialization in the near future, which could enhance the company's market position.
- Positive Market Reaction: Following the analyst's report, Biohaven's stock surged over 10% in a single trading session, indicating investor optimism about the company's future and heightened expectations surrounding its clinical trial outcomes.
- Favorable Investment Timing: Kulkami believes that now is an opportune time to buy Biohaven shares, especially ahead of the anticipated clinical trial results, which could lead to substantial returns for investors if the outcomes are favorable.
See More
Biohaven Reports New Clinical Data on Innovative Therapies
- Clinical Data Release: Biohaven presented new patient data on its BHV-1300 MoDE degrader for Graves' disease and BHV-1400 TRAP degrader for IgA nephropathy at the Yale Innovation Summit, showcasing the potential of its therapies to transform treatment options for autoimmune diseases.
- R&D Day Event: The data was unveiled during Biohaven's 2026 R&D and Analyst Day at Yale School of Management, highlighting the company's innovative capabilities in the biopharmaceutical sector and its focus on autoimmune diseases, which may attract increased investor interest.
- Platform Technology Advantage: Biohaven's proprietary MoDE™ and TRAP™ degrader platforms demonstrate unique drug development capabilities that could provide a competitive edge in future clinical trials, enhancing its position in the biopharmaceutical market.
- Broad Market Prospects: With the rising number of autoimmune disease patients, Biohaven's new therapies are poised to address unmet medical needs, further driving the company's expansion and revenue growth in the global market.
See More
Biohaven's New Therapies Show Significant Antibody Reduction
- Efficacy of BHV-1300: In a 12-week study, patients with Graves' disease receiving 1000 mg of BHV-1300 weekly showed an average reduction of over 80% in pathogenic TSHR-IgG1 antibodies, indicating the drug's potential as a first effective disease-modifying therapy for Graves' disease.
- Rapid Normalization of Thyroid Hormones: Patients experienced normalization of T4 levels within a median of 3 weeks and T3 levels within 5 weeks after the first administration, demonstrating BHV-1300's ability to quickly restore thyroid function, addressing a critical unmet need for effective treatments.
- Rapid Action of BHV-1400: In patients with IgA nephropathy, BHV-1400 achieved over 60% mean reduction in Gd-IgA1 antibodies within 48 hours and 70% within one month, showcasing its rapid and profound impact on treating IgAN.
- Good Safety Profile: Both BHV-1300 and BHV-1400 showed no serious adverse events during clinical trials, with most adverse reactions being mild and self-resolving, indicating a competitive safety advantage that may encourage more patients to participate in upcoming Phase 3 trials.
See More
Biohaven Reports New Data on Opakalim for Epilepsy Treatment
- Clinical Trial Progress: Biohaven will present new data on Opakalim's Phase 2/3 studies for focal epilepsy at its upcoming R&D Day, indicating its potential to provide more effective treatment options for patients in seizure control.
- Safety Advantages: Opakalim demonstrated zero rates of somnolence, dizziness, and fatigue in a small proof-of-concept study, suggesting that its selective Kv7.2/7.3 activation mechanism may offer better tolerability, enhancing patients' quality of life.
- Patient Case Update: A 9-year-old patient with KCNQ2-DEE showed seizure control after transitioning to Opakalim, highlighting the drug's efficacy in treatment-resistant epilepsy patients and supporting its clinical application potential.
- Future Outlook: Biohaven is on track to announce top-line results from two pivotal Phase 2/3 randomized double-blind studies in the second half of 2026, aiming to support Opakalim's registration and advance its commercialization efforts.
See More
Biohaven Reports New Clinical Data on Opakalim for Epilepsy Treatment
- Breakthrough in Epilepsy Treatment: In a randomized controlled trial, the median time to the second generalized tonic-clonic seizure was 141 days for the Opakalim 75 mg once-daily group compared to 47 days for the placebo group, indicating a threefold prolongation and highlighting its potential in treating refractory epilepsy.
- Significant Efficacy: In an ongoing open-label extension study, 54% of patients with focal epilepsy achieved a ≥50% reduction in seizure frequency on Opakalim, demonstrating comparable efficacy to other Kv7 activators but with significantly lower side effects.
- Safety Advantage: Opakalim has shown excellent tolerability across studies, with over 1,000 subjects reporting adverse event rates below 5%, marking a significant improvement over other antiseizure medications in terms of central nervous system side effects.
- Future Outlook: Biohaven is on track to announce top-line results from two pivotal Phase 2/3 trials in the second half of 2026, which will support the registration of Opakalim and further solidify its market position in epilepsy treatment.
See More
Biohaven Q1 Earnings Miss Expectations
- Earnings Miss: Biohaven reported a Q1 GAAP EPS of -$0.88, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, Biohaven's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $351.8 million, providing some liquidity but necessitating scrutiny on future capital efficiency.
- Rating Downgrade Impact: The stock was downgraded to 'Hold' due to setbacks with Troriluzole and potential implications from obesity data expected in the second half of 2026, prompting a reassessment of the company's growth prospects.
- Market Reaction Outlook: Analysts' quant ratings reflect a cautious stance on Biohaven's future performance, urging investors to closely monitor subsequent financial and R&D developments to evaluate long-term investment value.
See More
Biohaven Stock Surges 10.14% Following Analyst Buy Rating
- Analyst Strong Buy: Sumant Kulkami from Canaccord Genuity initiated coverage on Biohaven with a bullish buy rating and a price target of $21 per share, indicating a potential upside of over 100% from current levels, reflecting strong confidence in the company's growth prospects.
- Clinical Trial Progress: Biohaven's drug Opakalim is currently in phase 3 clinical testing for epilepsy, and Kulkami expressed satisfaction with its performance, suggesting significant potential for commercialization in the near future, which could enhance the company's market position.
- Positive Market Reaction: Following the analyst's report, Biohaven's stock surged over 10% in a single trading session, indicating investor optimism about the company's future and heightened expectations surrounding its clinical trial outcomes.
- Favorable Investment Timing: Kulkami believes that now is an opportune time to buy Biohaven shares, especially ahead of the anticipated clinical trial results, which could lead to substantial returns for investors if the outcomes are favorable.
See More
